<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00367341</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00026176</org_study_id>
    <nct_id>NCT00367341</nct_id>
  </id_info>
  <brief_title>Imaging Predictors of Treatment Response in Depression</brief_title>
  <official_title>Imaging Predictors of Treatment Response in Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      While there are many effective options for treating a major depressive episode, there are no
      clinical markers that predict the likelihood of remission with an initial trial of either an
      antidepressant medication or psychotherapy. More critically, there are also no reliable
      predictors that might anticipate failure to such standard treatments either alone or in
      combination. This project will characterize imaging-based brain subtypes that distinguish
      groups of depressed patients who later remit or not to SSRI pharmacotherapy or cognitive
      behavior therapy (CBT), respectively. To define these subtypes, a prospectively-treated
      cohort of 100 patients will be randomized to receive either escitalopram (s-CIT) or CBT for
      the first 12 weeks, with non-remitters to either first treatment crossed over to receive an
      additional 12 weeks of treatment with combined treatment. Non-remitters to both treatments
      will thus define a relatively treatment resistant third subgroup. Resting-state
      18F-fluoro-deoxyglucose (FDG) positron emission tomography (PET) scans will be acquired prior
      to initiating antidepressant therapy, with pre-treatment scan patterns associated with three
      possible outcomes (CBT remission, s-CIT remission, and non-remission to both) assessed using
      multivariate analytic methods. A second PET scan, acquired early in the treatment course,
      will be used to assess the likelihood of response to the specific treatment first assigned.
      The proposed studies are a first step towards defining brain-based biomarkers predictive of
      differential treatment outcome in major depression; most critically, patterns distinguishing
      patients at risk for treatment resistance. Identification of such biomarkers has additional
      implications for future testing of novel therapies in patients with distinct brain
      signatures, including development of evidence-based treatment algorithms for individual
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SPECIFIC AIMS Aim 1. To define baseline regional glucose metabolic patterns (measured using
      FDG PET) associated with differential clinical remission to each of two well-established,
      randomly delivered first-line antidepressant treatmentsâ€”the SSRI escitalopram (s-CIT) or
      cognitive behavioral therapy (CBT) with cross-over treatment for non-remitters (sequential
      course of treatment model).

      Aim 2. To define metabolic change patterns, occurring early in the course of both s-CIT and
      CBT, associated with successful and unsuccessful clinical remission to each intervention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission Defined as Hamilton Depression Rating Scale-17 Score of Less Than or Equal to 7 at 12 Weeks</measure>
    <time_frame>Measured at week 12</time_frame>
    <description># of study participants with Hamilton Depression-17-item score less than or equal to 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Defined as 50% Change in Hamilton Depression Rating Scale-17 Score at 12 Weeks</measure>
    <time_frame>Measured at week 12.</time_frame>
    <description>Number of participants with a 50% change from Baseline on the Hamilton Depression Rating Scale-17-item score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognitive Behavioral Therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>Participants will receive treatment with escitalopram for 12 weeks.</description>
    <arm_group_label>Escitalopram</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy (CBT)</intervention_name>
    <description>CBT will include 16 1 hour sessions provided over 12 weeks.</description>
    <arm_group_label>Cognitive Behavioral Therapy</arm_group_label>
    <other_name>Talk Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients between the ages of 18 and 60. (no subjects with first episode
             over age 50. This is an attempt to exclude patients with 'vascular depression' who
             have a potentially different pathophysiology and treatment response compared to
             idiopathic MDD.

          -  DSM-IV criteria for unipolar Major Depressive Disorder.

          -  HAM-D (24 item) score &gt;/= 18 at Screening, &gt;/= 15 at Baseline.

          -  Co-morbid conditions (other than those listed under exclusion criteria below) will be
             accepted as long as MDD is the primary diagnosis (based on predominance and sequential
             development of symptoms).

          -  Acceptable method of birth control (oral contraceptives, Depo-Provera, Norplant,
             condoms with spermicide. A vasectomy is acceptable in the framework of a stable
             monogamous relationship. Sexually inactive women must agree to contraception if they
             become sexually active during the study.

          -  Educational level, degree of understanding and reliability so that participation is
             feasible.

          -  Informed consent to participate and comply in the study.

        Exclusion Criteria:

          -  Known neurological disorders or documented head injury.

          -  Serious and unstable medical illnesses including diabetes, cardiovascular disease and
             cancer.

          -  Medical conditions with known mood changes (endocrine, autoimmune disorders)

          -  Co-morbid DSM-IV Axis I Diagnoses

               1. Lifetime history of Bipolar Disorder, Schizophrenia, and other Psychotic
                  Disorders, or Obsessive Compulsive Disorder

               2. Alcohol abuse or dependence within the past six months, psychoactive substance
                  abuse or dependence within the past six months.

               3. Clinical evidence of a severe Personality Disorder that would impede
                  participation or completion of a controlled trial.

          -  ECT within the past 6 months.

          -  Previous failure to achieve a much improved status on CGI-Improvement (the equivalent
             of &gt;50% symptom reduction) with a course of CBT (defined as a minimum of 8 sessions
             during 8 weeks of a specified manual-driven therapy by a CBT trained therapist) or
             escitalopram (defined as a minimum of 6 weeks with the dose of 10 mgs achieved for at
             least 2 weeks)

          -  Use of concomitant medications with the exception of:

               1. Maintenance/prophylactic meds for stable medical conditions

               2. Ambien 5-10 mgs may be prescribed for occasional use (up to a single dose a week
                  for insomnia, as long as it is not the night before a clinic visit, PET/fMRI
                  study or ratings.

               3. Antidepressants will be discontinued for 7 days prior to the screening visit,
                  which will be a minimum of a week before the baseline scan (5 weeks for
                  fluoxetine, protryptyline).

          -  Current treatment with weekly individual or group psychotherapy targeted at the
             depressive symptoms, including psychodynamic, interpersonal or cognitive-behavioral.

          -  Currently responding to medication treatment, without clinical reasons to change (e.g.
             side effects). Will not enroll a subject who wishes to discontinue an effective
             treatment for the sake of participation in the research.

          -  Woman who are pregnant, breast feeding or intending to become pregnant during the
             course of the study.

          -  Contraindications for MRI: pacemaker, aneurysm clips, neurostimulators, cochlear
             implants, metal in eyes, steel worker, or other implants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Mayberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.emoryclinicaltrials.com</url>
    <description>website with study information</description>
  </link>
  <results_reference>
    <citation>McGrath CL, Kelley ME, Holtzheimer PE, Dunlop BW, Craighead WE, Franco AR, Craddock RC, Mayberg HS. Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry. 2013 Aug;70(8):821-9. doi: 10.1001/jamapsychiatry.2013.143.</citation>
    <PMID>23760393</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2006</study_first_submitted>
  <study_first_submitted_qc>August 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2006</study_first_posted>
  <results_first_submitted>November 21, 2013</results_first_submitted>
  <results_first_submitted_qc>November 21, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 9, 2014</results_first_posted>
  <last_update_submitted>November 21, 2013</last_update_submitted>
  <last_update_submitted_qc>November 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Helen Mayberg</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Depression, Treatment, Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Escitalopram</title>
          <description>escitalopram : Participants will receive treatment with escitalopram for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Cognitive Behavioral Therapy</title>
          <description>Cognitive Behavioral Therapy (CBT) : CBT will include 16 1 hour sessions provided over 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Escitalopram</title>
          <description>escitalopram : Participants will receive treatment with escitalopram for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Cognitive Behavioral Therapy</title>
          <description>Cognitive Behavioral Therapy (CBT) : CBT will include 16 1 hour sessions provided over 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.2" spread="6.8"/>
                    <measurement group_id="B2" value="42.2" spread="9.5"/>
                    <measurement group_id="B3" value="41.68" spread="8.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Remission Defined as Hamilton Depression Rating Scale-17 Score of Less Than or Equal to 7 at 12 Weeks</title>
        <description># of study participants with Hamilton Depression-17-item score less than or equal to 7.</description>
        <time_frame>Measured at week 12</time_frame>
        <population>completed study participants in 12-week-trial</population>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram</title>
            <description>escitalopram : Participants will receive treatment with escitalopram for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cognitive Behavioral Therapy</title>
            <description>Cognitive Behavioral Therapy (CBT) : CBT will include 16 1 hour sessions provided over 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Remission Defined as Hamilton Depression Rating Scale-17 Score of Less Than or Equal to 7 at 12 Weeks</title>
          <description># of study participants with Hamilton Depression-17-item score less than or equal to 7.</description>
          <population>completed study participants in 12-week-trial</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Defined as 50% Change in Hamilton Depression Rating Scale-17 Score at 12 Weeks</title>
        <description>Number of participants with a 50% change from Baseline on the Hamilton Depression Rating Scale-17-item score</description>
        <time_frame>Measured at week 12.</time_frame>
        <population>completers</population>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram</title>
            <description>escitalopram : Participants will receive treatment with escitalopram for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cognitive Behavioral Therapy</title>
            <description>Cognitive Behavioral Therapy (CBT) : CBT will include 16 1 hour sessions provided over 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Defined as 50% Change in Hamilton Depression Rating Scale-17 Score at 12 Weeks</title>
          <description>Number of participants with a 50% change from Baseline on the Hamilton Depression Rating Scale-17-item score</description>
          <population>completers</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Escitalopram</title>
          <description>escitalopram : Participants will receive treatment with escitalopram for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Cognitive Behavioral Therapy</title>
          <description>Cognitive Behavioral Therapy (CBT) : CBT will include 16 1 hour sessions provided over 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>indigestion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>stomach cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>decreased libido</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>sedation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>flu</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Helen Mayberg, MD</name_or_title>
      <organization>Emory University School of Medicine</organization>
      <phone>404-727-6740</phone>
      <email>hmayber@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

